Navigation Links
NUNC Polyester Sealing Tape, White, Sterile

ProductsNUNC Polyester Sealing Tape, White, Sterile
Company Nunc Brand Products
Item NUNC Polyester Sealing Tape, White, Sterile
Features Inquire
Description Sealing tape featuring 3M adhesive technology. Opaque and strong. Prevents photo-degradation.
Info Nunc Brand Products
Customer Service: (585) 586-8800
Web site: http://www.nuncbrand.com

Related medicine products :

1. NUNC Polyester Sealing Tape, Clear, Sterile
2. NUNC Polyester Sealing Tape, Clear, Non-Sterile
3. Eppendorf Heat Sealing Film
4. 96-Well Plate Sealing Film
5. PVC Sealing Tape
6. Sealing Tape Pads for Empore 96 Well Plates
7. NUNC Polyolefin Sealing Tape, Clear, Non-Sterile
8. NUNC Polyolefin Sealing Tape, Clear, Non-Sterile, Certified DNAse/RNAse-free
9. NUNC Rayon Breathable Sealing Tape
10. NUNC Advanced Piercable Polyethylene Sealing Tape, Clear, Non-Sterile
11. Sealing Tape
...reatly improved with Volk's exclusive Double Asphe... precise and focused laser beam placement at the c...ng and laser treatment of the posterior capsule. T...indow for optimal laser beam transmission and imag...
...offers extremely high resolution treatment capabil...exceptionally wide 78° field of view. This len...f the optic nerve head and macula. Excellent stere...edesigned to reduce weight and size. High magnific...
...ent for critically evaluating and treating subreti...generation, retinal vascular occlusions, diabetic ...and other retinal conditions. It is ideal for foca...cellent magnification combined with a good field o...
...ns has grown in popularity since its introduction ...ens. Its sleek 28.6mm diameter housing provides a ...ses for peripheral retinal viewing, reflection dis... for small pupil fundus examination and as a gener...
Medicine Products:
(Date:10/6/2008)...t. 6 /PRNewswire/ -- Developed in collaboration wi...ades, CA is introducing,Revolutionary Breast Surfa...c Surgery office of Dr. Steve Laverson this week i...he first of its kind, and is based on,breakthrough...with,innovative proprietary software. The XS-300(T...
(Date:10/6/2008)...ct. 6 /PRNewswire/ -- The organizers of Informex a...e on Global Sourcing for the,Pharmaceutical Indust...inceton Marriott in New Jersey USA., The conferen... the,Global Sourcing Council, and boasts an unpara...e likes of Johnson & Johnson, Bristol Myers Squibb...
(Date:10/6/2008)... LegalView recently posted detailed inform...he potentially serious side effects caused by the ... the drug,s potential side effects are the develop... for young adult and child patients. , ...- LegalView, the number one resource for everythin...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rece...Garden Valley, Texas October 6, 2008 -- www.seamob...l provider of communications services to remote lo...s to the FoxNews channel via satellite to Mercy Sh...ica Mercy. The Africa Mercy is the world,s larges...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3
...month phase of a calorie-restriction study conduct... Center on Aging (USDA HNRCA) at Tufts University...hem in check may be an important component of weig... from the Comprehensive Assessment of the Long-ter...
... of your workout may metabolize more fat than exer...dy in Japan . Researchers conducted the first kno...cising continually in one long bout versus breakin...d. The findings could change the way we approach e...
...spond to drugs that combat the AIDS virus can see ...njoyed by people without HIV, a study published o...ds light on poorly understood conditions as to why... can boost and maintain their CD4 immune cells, ot...
...s, boasts of almost a thousand no-sex-till-marriag...rogram-Virginity Rules . Its brand ambassador bea...al abstinence for the group, which has risen from ...to become an eight-county abstinence franchise. P...
Other Medicine News:Health News:Food Cravings are Linked to Weight Managenemt 2Health News:Food Cravings are Linked to Weight Managenemt 3Health News:Take a Break Inbetween Exercise 2Health News:Take a Break Inbetween Exercise 3Health News:HIV Drug Combo can Boost Immune Marker in Long-term Patients: Study 2Health News:Virginity Rules-Meant To Be Broken? 2Health News:Virginity Rules-Meant To Be Broken? 3
(Date:10/2/2008)...ndicate Dual Modes of Action and Synergy with Chem...- Access Pharmaceuticals, Inc.,(OTC Bulletin Board...studies on Angiolix showing that by blocking lacta...t as well as a direct anti-proliferative effect on... breast cancer (MX-1),Angiolix had a significant ...
(Date:10/1/2008)... the therapeutic potential of Amylin,s integrated ... pharmacotherapy, SAN DIEGO, Oct. 1 /PRNewswire-F... AMLN ) today announced that new data for its pip...2008 Annual Scientific Meeting of The,Obesity Soci...annual,meeting is one of the largest and most comp...
(Date:10/1/2008)...(R) (zolpidem tartrate sublingual lozenge) develop... in the middle of the night when patients .... RICHMOND, Calif., Oct. 1 /- Transce...ty pharmaceutical company, announced today,that it... U.S. Food and,Drug Administration (FDA) for its l...
(Date:10/1/2008)...l Study to Provide Real-World Dosing Simulation of...ibitor, INDIANAPOLIS, Oct. 1 /PRNewswire-FirstCal...nounced it will begin enrolling patients in a seco...inhibitor being investigated,as a potential treatm...lzheimer,s disease. The study, called IDENTITY 2, ...
Breaking Medicine Technology:Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 2Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 3Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 4Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 6Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound 2Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound 3Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound 4Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound 5Has cancer spread 3F Research identifies best way to find answers so treatment can begin 24260 1Has cancer spread 3F Research identifies best way to find answers so treatment can begin 24260 2Tips from the Journals of the American Society for Microbiology 4145 1Tips from the Journals of the American Society for Microbiology 4145 2Tips from the Journals of the American Society for Microbiology 4145 3Insmed CEO to Present at Congressional Briefing on Follow On Biologics 2682 1Insmed CEO to Present at Congressional Briefing on Follow On Biologics 2682 2Insmed CEO to Present at Congressional Briefing on Follow On Biologics 2682 3First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval 2679 1First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval 2679 2First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval 2679 3First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval 2679 4First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval 2679 5
...2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) to...nical trial studying CRx-139 (a synergistic,combin...aroxetine),and 3mg prednisolone alone, in patients... two important purposes. One purpose was to,determ...y low dose),in RA and to contrast this effect with...
...07 - Inotek,Pharmaceuticals Corporation announced ...l data demonstrating the safety of INO-1001,as wel...agent for,cardiac reperfusion injury. The study wa...cardial infarction (STEMI) undergoing,primary perc...as,made in a poster session at the American Colleg...
Other Medicine Technology:CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 2CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 3CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 4CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 5CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 6Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4